Clinical trial
Pembrolizumab in Treating Patients With Malignant Mesothelioma
NCT02399371
Study timeline
Study start (actual)2015-03-31Date precision: day
Registry last updated2026-05-08
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Biphasic Mesotheliomaunresolved
Epithelioid Mesotheliomaunresolved
Peritoneal Malignant Mesotheliomaunresolved
Pleural Biphasic Mesotheliomaunresolved
Pleural Epithelioid Mesotheliomaunresolved
Pleural Malignant Mesotheliomaunresolved
Pleural Sarcomatoid Mesotheliomaunresolved
Recurrent Pleural Malignant Mesotheliomaunresolved
Sarcomatoid Mesotheliomaunresolved
Interventions
Sponsors & collaborators
University of Chicagolead sponsor
National Cancer Institute (NCI)collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02399371 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.